Edison Investment Research - Midatech Pharma (MTPH) Midatech Pharma - Pivoting its commercial strategy

Report

Edison Investment Research

Sean Conroy

Midatech Pharma - Pivoting its commercial strategy

Midatech is a drug-delivery technology company focused on re-engineering existing therapeutics to improve their bioavailability and delivery. A strategic review in 2020 has translated into a broadened pipeline with the Q Sphera platform at its core (polymer microsphere technology for sustained drug release). The most clinically advanced asset is the Phase II ready MTX110 (MidaSolve platform, which liquifies insoluble oral therapies for improved drug delivery) targeting brain cancers such as diffuse intrinsic pontine glioma (DIPG) and glioblastoma (GBM). Prospective out-licensing deals for the Q-Sphera portfolio and start of the MTX110 Phase II trials in the coming months should be the next catalysts.

17/09/2021 18 EN

Underlying

Midatech Pharma

Midatech Pharma is a holding company. Through its subsidiaries, Co. is engaged as a specialty pharmaceutical company focused on the development and commercialization of multiple therapeutic products, using its nanomedicine and sustained release technologies, to enhance the delivery of medicines in major diseases with high unmet medical needs. These diseases include diabetes, certain cancers such as liver, ovarian and brain (glioblastoma) and neurological/ophthalmologic conditions. Co.'s two platform technologies are designed to enable targeted delivery and sustained release of existing therapeutic drugs to the "right place" at the "right time."

See profile

GB00BRTL9B63 United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

SmartInsider

1 director bought

A director at Midatech Pharma bought 450,000 shares at 6.8p and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board ...

Free Trial

October 7, 2019 October 7, 2019 1 EN

proactiveinvestors

Capital Network: Midatech Pharma PLC - Addressing high unmet need in cancer markets

A fully integrated specialty pharma company, Midatech Pharma is rapidly progressing the development of three lead R&D programs. They have developed three proprietary drug delivery technologies (Q-Sphera, Gold Nano Particle and Nano Inclusion) to improve and expand the therapeutic potential of validated drug products. At the same time Midatech has built a US commercial unit focused on supportive care products.

March 14, 2018 March 14, 2018 4 EN

Electro Optic Systems - Growth from defence

Electro Optic Systems (EOS) is an optic technology company specialising in defence applications, primarily remote weapons systems (RWS) and maritime communications. The company is benefiting from increased defence spending, is well-positioned in the new frontier of drone warfare and brings optionality in future battlefield arenas of high-energy laser weapons (HELWs) and space. Improved H1 results, a strong balance sheet and an extensive pipeline position EOS to benefit from such dynamics.

17h / 9m 17h / 9m 1 EN

Toby Thorrington

Toby Thorrington

Smiths News - FY24 trading good, special dividend proposed

Smiths News’ FY24 trading was robust and results came in ahead of consensus. This, along with the debt refinancing announced in May, has resulted in lower average debt, which in turn has allowed the company to implement its revised capital allocation policy (communicated in May) and its diversification ambitions. Furthermore, it has lifted its total ordinary dividend from 4.15p to 5.15p/share and announced a ‘special’ dividend of a further 2.0p/share.

17h / 23m 17h / 23m 1 EN

Sean Conroy

Sean Conroy

IRLAB Therapeutics - Progress across the pipeline in Q324

IRLAB’s Q324 results highlighted progress across its clinical pipeline. Pirepemat cleared its final safety review and completed patient enrolment in the Phase IIb trial, making way for top-line readouts in Q125. IRL757 also made headway, reporting positive interim data from the first Phase I study and the initiation of a second study in older adults, triggering a US$2.5m (SEK26.6m) milestone payment from MSRD. Mesdopetam reported support from regulators in Germany and Portugal for the planned Phase III design, bolstering upcoming discussions with the EMA. This comes amid efforts by IRLAB towar...

November 4, 2024 November 4, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Midatech Pharma - Pivoting its commercial strategy

1 director bought

Capital Network: Midatech Pharma PLC - Addressing high unmet need in cancer markets

Electro Optic Systems - Growth from defence

Smiths News - FY24 trading good, special dividend proposed

IRLAB Therapeutics - Progress across the pipeline in Q324

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe